A few years ago a great clinical stage (P2) Aussie biotech sold out to major BP at a significant discount to its 'intrinsic value' after its SP was cleverly driven down in a concerted effort by 'smart money'.
BP picked up a bargain - long term SH's were just pleased to get out with a modest return after months/year or so of SP being dumped - on the back of great clinical data.
I'm smelling the same game being played with Immutep.
Clinical data success = BP (our customers) want in at the lowest cost - eventually. Drive down SP - frustrate SH's and opportunity to go in for the 'kill'.
The only way to bypass this (limited potential customers -2 or 3 BP) is to go it alone - solo and be prepared to go all the way to drug commercialisation and sale of product.
If this strategy is clearly articulated by Marc - basically saying F'U big pharma, then I'm in.
But IMO Marc is hedging his bets which could end up with the worst of both worlds.
- Forums
- ASX - By Stock
- IMM
- Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC
Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC, page-38
-
- There are more pages in this discussion • 71 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
34.5¢ |
Change
0.005(1.47%) |
Mkt cap ! $501.1M |
Open | High | Low | Value | Volume |
34.0¢ | 36.0¢ | 33.5¢ | $2.184M | 6.253M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 156342 | 34.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
35.0¢ | 107414 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 156342 | 0.345 |
8 | 173610 | 0.340 |
5 | 216592 | 0.335 |
11 | 170484 | 0.330 |
5 | 23066 | 0.325 |
Price($) | Vol. | No. |
---|---|---|
0.350 | 107414 | 4 |
0.355 | 87437 | 2 |
0.360 | 96232 | 4 |
0.365 | 117195 | 6 |
0.370 | 119996 | 5 |
Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |